HM Payson & Co. Has $1.25 Million Stake in Shire PLC (SHPG)
HM Payson & Co. decreased its position in Shire PLC (NASDAQ:SHPG) by 8.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,560 shares of the biopharmaceutical company’s stock after selling 676 shares during the period. HM Payson & Co.’s holdings in Shire PLC were worth $1,249,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. HPM Partners LLC acquired a new stake in shares of Shire PLC during the first quarter worth $1,534,000. Vanguard Group Inc. increased its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares during the last quarter. BlackRock Inc. increased its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares during the last quarter. Laurion Capital Management LP acquired a new stake in shares of Shire PLC during the first quarter worth $10,611,000. Finally, Atria Investments LLC increased its stake in shares of Shire PLC by 32.6% in the second quarter. Atria Investments LLC now owns 1,648 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 405 shares during the last quarter. Institutional investors own 20.22% of the company’s stock.
Shire PLC (SHPG) opened at 145.55 on Friday. Shire PLC has a 12 month low of $144.18 and a 12 month high of $209.22.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The company had revenue of $3.75 billion during the quarter. During the same period last year, the business earned $3.38 EPS. The firm’s quarterly revenue was up 54.2% on a year-over-year basis. On average, equities analysts expect that Shire PLC will post $14.91 earnings per share for the current fiscal year.
The business also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share. This represents a yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 40.63%.
A number of brokerages have weighed in on SHPG. Royal Bank Of Canada set a $221.00 target price on Shire PLC and gave the stock a “buy” rating in a report on Thursday, May 18th. HSBC Holdings plc downgraded Shire PLC from a “hold” rating to a “reduce” rating in a report on Friday, May 19th. Sanford C. Bernstein downgraded Shire PLC from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $209.22 to $161.09 in a report on Thursday, May 25th. BidaskClub upgraded Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, ValuEngine downgraded Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have issued a buy rating to the company. Shire PLC has an average rating of “Buy” and a consensus price target of $220.08.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.